Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

Improved RA classification among early arthritis patients with the concordant presence of three RA autoantibodies: analysis in two early arthritis clinics.

Regueiro C, Rodríguez-Martínez L, Nuño L, Ortiz AM, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, Gonzalez A.

Arthritis Res Ther. 2019 Dec 11;21(1):280. doi: 10.1186/s13075-019-2079-4.

PMID:
31829260
2.

Treat-To-Target and Treat-To-Budget in Rheumatoid Arthritis: Measuring the Value of Individual Therapeutic Interventions.

Sacristán JA, Díaz S, de la Torre I, Inciarte-Mundo J, Balsa A.

Rheumatol Ther. 2019 Dec;6(4):473-477. doi: 10.1007/s40744-019-00178-3. Epub 2019 Oct 30.

3.

"There is something you must see": breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective.

Acebes C, Andreu JL, Balsa A, Batlle E, de Toro-Santos J, García Llorente F, Hernández MV, Fernandez-Guiterrez B, Hidalgo-Calleja C, Mayordomo L, Naredo E, Narváez FJ, Ortiz AM, Pablos JL, Pérez-Sandoval T, Rodriguez-Lozano C, Sánchez-Pernaute O, Usón J, Negrón JB, Loza E, Carmona L, Gómez Castro S, Montoro Alvarez M.

Clin Exp Rheumatol. 2019 Sep 18. [Epub ahead of print]

PMID:
31573477
4.

Low serum calprotectin levels correlate with the presence of biological drugs after the first year of treatment in patients with rheumatoid arthritis.

Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Jochems A, Hernández-Breijo B, Peiteado D, Tornero C, Pascual-Salcedo D, Balsa A.

Scand J Clin Lab Invest. 2019 Nov;79(7):538-540. doi: 10.1080/00365513.2019.1669813. Epub 2019 Sep 27. No abstract available.

PMID:
31561717
5.

Biosimilar and interchangeable: Inseparable scientific concepts?

de Mora F, Balsa A, Cornide-Santos M, Carrascosa JM, Marsal S, P Gisbert J, Abad MA, F Duarte R, Wiechmann M, Martínez R.

Br J Clin Pharmacol. 2019 Nov;85(11):2460-2463. doi: 10.1111/bcp.14089. Epub 2019 Sep 4. No abstract available.

6.

Reduction in antidrug antibody levels after switching to rituximab in patients with rheumatoid arthritis with prior infliximab or adalimumab secondary failure.

Martínez Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, Nozal P, Ángeles González M, Nuño L, Monjo I, Pascual-Salcedo D, Balsa A.

Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30213-6. doi: 10.1016/j.semarthrit.2019.06.021. [Epub ahead of print] No abstract available.

PMID:
31375255
7.

Unilateral diffuse alveolar hemorrhage in granulomatosis with polyangiitis.

Collada JM, Bonilla G, Gómez-Carrera L, De Miguel E, Verdasco AM, Balsa A.

Clin Rheumatol. 2019 Oct;38(10):2951-2952. doi: 10.1007/s10067-019-04688-x. Epub 2019 Jul 23. No abstract available.

PMID:
31332692
8.

Positive ultrasound halo sign of temporal arteries due to amyloidosis.

Molina Collada J, Ruíz Bravo-Burguillos E, Monjo I, Bonilla G, Fernández E, Balsa A, De Miguel E.

Rheumatology (Oxford). 2019 Nov 1;58(11):2067-2069. doi: 10.1093/rheumatology/kez182. No abstract available.

PMID:
31079154
9.

Two populations of circulating PD-1hiCD4 T cells with distinct B cell helping capacity are elevated in early rheumatoid arthritis.

Fortea-Gordo P, Nuño L, Villalba A, Peiteado D, Monjo I, Sánchez-Mateos P, Puig-Kröger A, Balsa A, Miranda-Carús ME.

Rheumatology (Oxford). 2019 Sep 1;58(9):1662-1673. doi: 10.1093/rheumatology/kez169.

PMID:
31056653
10.

Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib.

Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M.

Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. No abstract available.

11.

Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept.

Ferreiro-Iglesias A, Montes A, Perez-Pampin E, Cañete JD, Raya E, Magro-Checa C, Vasilopoulos Y, Caliz R, Ferrer MA, Joven B, Carreira P, Balsa A, Pascual-Salcedo D, Blanco FJ, Moreno-Ramos MJ, Manrique-Arija S, Ordoñez MDC, Alegre-Sancho JJ, Narvaez J, Navarro-Sarabia F, Moreira V, Valor L, Garcia-Portales R, Marquez A, Gomez-Reino JJ, Martin J, Gonzalez A.

PLoS One. 2019 Feb 28;14(2):e0213073. doi: 10.1371/journal.pone.0213073. eCollection 2019.

12.

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis.

Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, Wolbink GJ, Rispens T, Diego C, Pascual-Salcedo D, Balsa A.

Arthritis Res Ther. 2019 Feb 20;21(1):66. doi: 10.1186/s13075-019-1849-3.

13.

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.

González-Fernández MÁ, Villamañán E, Jiménez-Nácher I, Moreno F, Herrero A, Balsa A.

Farm Hosp. 2019 Jan 1;43(1):24-30. doi: 10.7399/fh.11080.

14.

The effect of methotrexate versus other disease-modifying anti-rheumatic drugs on serum drug levels and clinical response in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors.

Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Hernández-Breijo B, González MÁ, Monjo I, Nuño L, Nozal P, Pascual-Salcedo D, Balsa A.

Clin Rheumatol. 2019 Mar;38(3):949-954. doi: 10.1007/s10067-018-4355-0. Epub 2018 Nov 6.

PMID:
30402698
15.

Practical Aspects of Biological Throughput Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis.

Rosas J, Martín-López M, Otón T, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Carmona L.

Reumatol Clin. 2018 Oct 29. pii: S1699-258X(18)30220-1. doi: 10.1016/j.reuma.2018.09.006. [Epub ahead of print] English, Spanish.

16.

Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis.

Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A, Nuño L, Castaño-Nuñez AL, Villalva A, Perez-Pampin E, Lopez-Golan Y, Abasolo L, Ortiz AM, Herranz E, Pascual-Salcedo D, Martínez-Feito A, Boveda MD, Gomez-Reino JJ, Martín J, Gonzalez-Escribano MF, Fernandez-Gutierrez B, Balsa A, Gonzalez-Alvaro I, Gonzalez A.

Arthritis Rheumatol. 2019 Mar;71(3):331-339. doi: 10.1002/art.40738. Epub 2019 Jan 28.

PMID:
30277011
17.

Identification of a 3'-Untranslated Genetic Variant of RARB Associated With Carotid Intima-Media Thickness in Rheumatoid Arthritis: A Genome-Wide Association Study.

López-Mejías R, Carmona FD, Genre F, Remuzgo-Martínez S, González-Juanatey C, Corrales A, Vicente EF, Pulito-Cueto V, Miranda-Filloy JA, Ramírez Huaranga MA, Blanco R, Robustillo-Villarino M, Rodríguez-Carrio J, Alperi-López M, Alegre-Sancho JJ, Mijares V, Lera-Gómez L, Pérez-Pampín E, González A, Ortega-Castro R, López-Pedrera C, García Vivar ML, Gómez-Arango C, Raya E, Narvaez J, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Gualillo O, Castañeda S, Martín J, Llorca J, González-Gay MA.

Arthritis Rheumatol. 2019 Mar;71(3):351-360. doi: 10.1002/art.40734. Epub 2019 Jan 18.

18.

Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price.

González-Fernández M, Villamañán E, Jiménez-Nácher I, Moreno F, Plasencia C, Gaya F, Herrero A, Balsa A.

Int J Clin Pharm. 2018 Dec;40(6):1528-1538. doi: 10.1007/s11096-018-0703-z. Epub 2018 Sep 8.

PMID:
30196515
19.

Association of a rare variant of the TNFSF13B gene with susceptibility to Rheumatoid Arthritis and Systemic Lupus Erythematosus.

González-Serna D, Ortiz-Fernández L, Vargas S, García A, Raya E, Fernández-Gutierrez B, López-Longo FJ, Balsa A, González-Álvaro I, Narvaez J, Gómez-Vaquero C, Sabio JM, García-Portales R, González-Escribano MF, Tolosa C, Carreira P, Kiemeney L, Coenen MJH, Witte T, Schneider M, González-Gay MÁ, Martín J.

Sci Rep. 2018 May 29;8(1):8195. doi: 10.1038/s41598-018-26573-4.

20.

Golimumab Tapering Strategy Based on Serum Drug Levels in Patients With Spondyloarthritis.

Redondo C, Martínez-Feito A, Plasencia-Rodríguez C, Navarro-Compán V, Nuño-Nuño L, Peiteado D, Villalba A, Jochems A, Pascual-Salcedo D, Balsa A.

Arthritis Rheumatol. 2018 Aug;70(8):1356-1358. doi: 10.1002/art.40542. Epub 2018 Jul 2. No abstract available.

21.

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis.

Lopez-Rodriguez R, Perez-Pampin E, Marquez A, Blanco FJ, Joven B, Carreira P, Ferrer MA, Caliz R, Valor L, Narvaez J, Cañete JD, Ordoñez MDC, Manrique-Arija S, Vasilopoulos Y, Balsa A, Pascual-Salcedo D, Moreno-Ramos MJ, Alegre-Sancho JJ, Navarro-Sarabia F, Moreira V, Garcia-Portales R, Raya E, Magro-Checa C, Martin J, Gomez-Reino JJ, Gonzalez A.

PLoS One. 2018 May 7;13(5):e0196793. doi: 10.1371/journal.pone.0196793. eCollection 2018.

22.

Takotsubo Cardiomyopathy Associated with Levothyroxine Over-replacement.

Balsa AM, Ferreira AR, Alves M, Guimarães J.

Eur Endocrinol. 2017 Apr;13(1):30-32. doi: 10.17925/EE.2017.13.01.30. Epub 2017 Apr 3.

23.

Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review.

Martín-López M, Carmona L, Balsa A, Calvo-Alén J, Sanmartí R, Tornero J, Rosas J.

Rheumatol Int. 2018 Jun;38(6):975-983. doi: 10.1007/s00296-018-4022-4. Epub 2018 Apr 3.

PMID:
29616303
24.

Lipid Profile in Relation to Glycemic Control in Type 1 Diabetes Children and Adolescents in Bangladesh.

Zabeen B, Balsa AM, Islam N, Parveen M, Nahar J, Azad K.

Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):89-92. doi: 10.4103/ijem.IJEM_217_17.

25.

The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature.

Balsa A, Lula S, Marshall L, Szczypa P, Aikman L.

Expert Opin Biol Ther. 2018 May;18(5):575-584. doi: 10.1080/14712598.2018.1450385. Epub 2018 Mar 20.

PMID:
29533116
26.

Differential blood cellular profile in patients with moderate-to-severe psoriasis treated with classical systemic therapies: a step forward in personalized medicine.

Hernández-Breijo B, Jurado T, Rodríguez-Martín E, Martínez-Feito A, Plasencia-Rodríguez C, Balsa A, Alonso-Pacheco ML, Villar LM, Herranz-Pinto P, Pascual-Salcedo D.

Br J Dermatol. 2018 Sep;179(3):765-766. doi: 10.1111/bjd.16537. Epub 2018 Jun 21. No abstract available.

PMID:
29526036
27.

Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study.

Balsa A, Sanmarti R, Rosas J, Martin V, Cabez A, Gómez S, Montoro M.

Rheumatology (Oxford). 2018 Apr 1;57(4):688-693. doi: 10.1093/rheumatology/kex474.

PMID:
29365183
28.

Adalimumab concentration-based tapering strategy: as good as the recommended dosage.

Mulleman D, Balsa A.

Ann Rheum Dis. 2018 Apr;77(4):473-475. doi: 10.1136/annrheumdis-2017-212376. Epub 2018 Jan 6. No abstract available.

29.

REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.

González-Álvaro I, Blasco AJ, Lázaro P, Sánchez-Piedra C, Almodovar R, Bachiller-Corral J, Balsa A, Caliz R, Candelas G, Fernández-Carballido C, García-Aparicio A, García-Magallón B, García-Vicuña R, Gómez-Centeno A, Ortiz AM, Sanmartí R, Sanz J, Tejera B.

Heliyon. 2017 Nov 14;3(11):e00452. doi: 10.1016/j.heliyon.2017.e00452. eCollection 2017 Nov.

30.

Use of Immunomodulatory Drugs at a Uveitis Clinic.

Millán-Longo C, Peiteado D, Schlincker A, Hidalgo V, Pieren A, Balsa A, de Miguel E.

Reumatol Clin. 2019 Sep - Oct;15(5):271-276. doi: 10.1016/j.reuma.2017.09.008. Epub 2017 Nov 11. English, Spanish.

31.

Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review.

Navarro-Compán V, Plasencia-Rodríguez C, de Miguel E, Diaz Del Campo P, Balsa A, Gratacós J.

RMD Open. 2017 Oct 10;3(2):e000524. doi: 10.1136/rmdopen-2017-000524. eCollection 2017.

32.

Optimal concentration range of golimumab in patients with axial spondyloarthritis.

Martínez-Feito A, Plasencia-Rodriguez C, Navarro-Compán V, Jurado T, Kneepkens EL, Wolbink GJ, Martín S, Ruiz Del Agua A, Navarro R, Mezcua A, Jochems A, Peiteado D, Bonilla MG, Balsa A, Pascual-Salcedo D.

Clin Exp Rheumatol. 2018 Jan-Feb;36(1):110-114. Epub 2017 Sep 15.

PMID:
28980904
33.

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients.

Regueiro C, Nuño L, Ortiz AM, Peiteado D, Villalba A, Pascual-Salcedo D, Martínez-Feito A, González-Alvaro I, Balsa A, González A.

Sci Rep. 2017 Sep 20;7(1):12023. doi: 10.1038/s41598-017-09657-5.

34.

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring in clinical practice: the spanish cohort of the COMORA study.

Balsa A, Lojo-Oliveira L, Alperi-López M, García-Manrique M, Ordóñez-Cañizares C, Pérez L, Ruiz-Esquide V, Corrales A, Narváez J, Rey-Rey J, Rodríguez-Lozano C, Ojeda S, Muñoz-Fernández S, Nolla JM, García-Torrón J, Gamero F, García-Vicuña R, Hernández-Cruz B, Campos J, Rosas J, García-Llorente JF, Gómez-Centeno A, Cáliz R, Sanmartí R, Bermúdez A, Abasolo-Alcázar L, Fernández-Nebro A, Rodríguez-Rodríguez L, Marras C, González-Gay MÁ, Hmamouchi I, Martín-Mola E.

Reumatol Clin. 2019 Mar - Apr;15(2):102-108. doi: 10.1016/j.reuma.2017.06.002. Epub 2017 Jul 12. English, Spanish.

35.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Rheumatoid Arthritis.

Medina F, Plasencia C, Goupille P, Ternant D, Balsa A, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):364-369. doi: 10.1097/FTD.0000000000000421. Review.

PMID:
28700520
36.

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.

Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L.

BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8. Review.

37.

Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach?

Acebes C, Andreu JL, Balsa A, Batlle E, de Toro-Santos J, García Llorente F, Hernández MV, Fernández-Gutiérrez B, Hidalgo-Calleja C, Mayordomo L, Naredo E, Narváez FJ, Ortiz AM, Pablos JL, Pérez-Sandoval T, Rodríguez-Lozano C, Sánchez-Pernaute O, Usón J, Negrón JB, Loza E, Carmona L, Gómez Castro S, Montoro Alvarez M.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):816-822. Epub 2017 May 8.

PMID:
28516881
38.

Evaluation of the Cross-reactivity of Antidrug Antibodies to CT-P13 and Infliximab Reference Product (Remicade): An Analysis Using Immunoassays Tagged with Both Agents.

Reinisch W, Jahnsen J, Schreiber S, Danese S, Panés J, Balsa A, Park W, Kim J, Lee JU, Yoo DH.

BioDrugs. 2017 Jun;31(3):223-237. doi: 10.1007/s40259-017-0219-4.

39.

Evaluation of Toll-like-receptor gene family variants as prognostic biomarkers in rheumatoid arthritis.

Torices S, Alvarez-Rodríguez L, Varela I, Muñoz P, Balsa A, López-Hoyos M, Martinez-Taboada V, Fernández-Luna JL.

Immunol Lett. 2017 Jul;187:35-40. doi: 10.1016/j.imlet.2017.04.011. Epub 2017 May 7.

PMID:
28495399
40.

Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Spondyloarthritis.

Medina F, Plasencia C, Goupille P, Paintaud G, Balsa A, Mulleman D.

Ther Drug Monit. 2017 Aug;39(4):360-363. doi: 10.1097/FTD.0000000000000400. Review.

PMID:
28379895
41.

Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).

Fautrel B, Balsa A, Van Riel P, Casillas M, Capron JP, Cueille C, de la Torre I.

Curr Med Res Opin. 2017 Jul;33(7):1231-1246. doi: 10.1080/03007995.2017.1313209. Epub 2017 Apr 28. Review.

PMID:
28358217
42.

Ultrasound sensitivity to changes in gout: a longitudinal study after two years of treatment.

Peiteado D, Villalba A, Martín-Mola E, Balsa A, De Miguel E.

Clin Exp Rheumatol. 2017 Sep-Oct;35(5):746-751. Epub 2017 Mar 3.

PMID:
28281462
43.

Influence of coronary artery disease and subclinical atherosclerosis related polymorphisms on the risk of atherosclerosis in rheumatoid arthritis.

López-Mejías R, Corrales A, Vicente E, Robustillo-Villarino M, González-Juanatey C, Llorca J, Genre F, Remuzgo-Martínez S, Dierssen-Sotos T, Miranda-Filloy JA, Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Ferraz-Amaro I, Gómez-Vaquero C, Balsa A, López-Longo FJ, Carreira P, González-Álvaro I, Ocejo-Vinyals JG, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2017 Jan 6;7:40303. doi: 10.1038/srep40303.

44.

[Evaluation of Uruguay's antismoking campaign: progress and challenges at ten years].

Triunfo P, Harris J, Balsa A.

Rev Panam Salud Publica. 2016 Oct;40(4):256-262. Spanish.

PMID:
28001202
45.

Exposures to Particulate Matter from the Eruptions of the Puyehue Volcano and Birth Outcomes in Montevideo, Uruguay.

Balsa AI, Caffera M, Bloomfield J.

Environ Health Perspect. 2016 Nov;124(11):1816-1822. Epub 2016 May 6.

46.

A functional variant of TLR10 modifies the activity of NFkB and may help predict a worse prognosis in patients with rheumatoid arthritis.

Torices S, Julia A, Muñoz P, Varela I, Balsa A, Marsal S, Fernández-Nebro A, Blanco F, López-Hoyos M, Martinez-Taboada V, Fernández-Luna JL.

Arthritis Res Ther. 2016 Oct 4;18(1):221.

47.

Influence of elevated-CRP level-related polymorphisms in non-rheumatic Caucasians on the risk of subclinical atherosclerosis and cardiovascular disease in rheumatoid arthritis.

López-Mejías R, Genre F, Remuzgo-Martínez S, González-Juanatey C, Robustillo-Villarino M, Llorca J, Corrales A, Vicente E, Miranda-Filloy JA, Magro C, Tejera-Segura B, Ramírez Huaranga MA, Pina T, Blanco R, Alegre-Sancho JJ, Raya E, Mijares V, Ubilla B, Mínguez Sánchez MD, Gómez-Vaquero C, Balsa A, Pascual-Salcedo D, López-Longo FJ, Carreira P, González-Álvaro I, Rodríguez-Rodríguez L, Fernández-Gutiérrez B, Ferraz-Amaro I, Castañeda S, Martín J, González-Gay MA.

Sci Rep. 2016 Aug 18;6:31979. doi: 10.1038/srep31979.

48.

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study.

Kneepkens EL, van den Oever I, Plasencia CH, Pascual-Salcedo D, de Vries A, Hart M, Nurmohamed MT, Balsa A, Rispens T, Wolbink G.

Scand J Rheumatol. 2017 Mar;46(2):87-94. doi: 10.1080/03009742.2016.1183039. Epub 2016 Jul 20.

PMID:
27440258
49.

Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Martin-Mola E, Balsa A, García-Vicuna R, Gómez-Reino J, González-Gay MA, Sanmartí R, Loza E.

Rheumatol Int. 2016 Aug;36(8):1043-63. doi: 10.1007/s00296-016-3506-3. Epub 2016 Jun 6. Review.

PMID:
27271502
50.

Comparing a tapering strategy to the standard dosing regimen of TNF inhibitors in rheumatoid arthritis patients with low disease activity.

Plasencia C, Wolbink G, Krieckaert CL, Kneepkens EL, Turk S, Jurado T, Martínez-Feito A, Navarro-Compán V, Bonilla G, Villalba A, Peiteado D, Nuño L, Martín-Mola E, Nurmohamed MT, van der Kleij D, Rispens T, Pascual-Salcedo D, Balsa A.

Clin Exp Rheumatol. 2016 Jul-Aug;34(4):655-62. Epub 2016 May 19.

PMID:
27214767

Supplemental Content

Support Center